Audentes Therapeutics, Inc. (NASDAQ:BOLD) is set to announce its earnings results on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.10). On average, analysts expect Audentes Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Audentes Therapeutics, Inc. (BOLD) opened at $25.02 on Monday. Audentes Therapeutics, Inc. has a 12-month low of $13.13 and a 12-month high of $33.43.

TRADEMARK VIOLATION WARNING: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.watchlistnews.com/audentes-therapeutics-inc-bold-to-release-quarterly-earnings-on-wednesday/1681801.html.

A number of research analysts have recently weighed in on BOLD shares. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research report on Monday, July 17th. ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Evercore ISI started coverage on Audentes Therapeutics in a research report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 price objective on the stock. Bank of America Corporation reaffirmed a “buy” rating and set a $33.00 price objective (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Finally, Raymond James Financial, Inc. began coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $25.71.

In related news, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $21.44, for a total transaction of $171,520.00. Following the sale, the vice president now owns 8,000 shares of the company’s stock, valued at approximately $171,520. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mary Newman sold 10,000 shares of Audentes Therapeutics stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the sale, the senior vice president now directly owns 10,000 shares in the company, valued at approximately $200,000. The disclosure for this sale can be found here. Insiders have sold a total of 766,500 shares of company stock worth $21,443,730 in the last three months. 47.30% of the stock is owned by corporate insiders.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.